Hdl-associated protein biomarker panel detection
AssigneeCleveland Heartlab, Inc.
InventorsCory Bystrom, Timothy Collier
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.
Claims24
A method comprising:
- detecting the level of at least one HDL-associated protein in a sample from a subject, wherein said at least one HDL-associated protein comprises ApoC3, and wherein said subject has, or is suspected of having, cardiovascular disease.
A system or composition comprising:
- a) a sample from a subject with, or suspected of having, cardiovascular disease;
- and
- b) a first component, wherein said first component comprises:
- i) an Apolipoprotein C3 (ApoC3) binding agent, and/or
- ii) a ApoC3 mass spectrometry standard.
A method of determining the approximate risk of cardiovascular disease and/or approximate reverse cholesterol transport capacity comprising:
- a) detecting, in a sample from a subject, the level of each of the HDL-associated proteins in Biomarker Panels 17, 18 and/or 19,
- wherein said Biomarker Panel 17 comprises proteins:
- ApoC1, ApoC2, and ApoC3;
- wherein said Biomarker Panel 18 comprises proteins:
- ApoA1, ApoC1, ApoC2, ApoC3, and ApoC4, and
- wherein said Biomarker Panel comprises proteins:
- ApoA2, ApoC1, ApoC2, ApoC3, ApoD, and SAA1/2;
- and
- b) determining the approximate risk of cardiovascular disease (CVD) for said subject, and/or the approximate cholesterol efflux capacity (CEC) of said sample.
Dependencies are inferred from the claim text.